Bristol Abilify Has 4% New Rx Share; Sales Force Size To Increase 50%

Bristol-Myers Squibb/Otsuka's Abilify has captured a 4% share of new antipsychotic prescriptions since its November launch, Bristol CEO Peter Dolan told investors on a first quarter conference call April 29